Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

Inclusion Criteria: * A recipient of a single or double lung transplant (including heart-lung transplant) * Age 18 years or older * Able to produce a forced expiratory volume in one second (FEV1) of greater than one liter at randomization * Eligible subjects must be enrolled within 70 days after receiving a lung transplant * Clinical status sufficiently stable to enable routine post-transplant bronchoscopy with bronchoalveolar lavage (BAL) and chest X-ray (or equivalent i.e., chest computerized tomogram (CT)) prior to screening Exclusion Criteria: * Lung re-transplantation * Documented allergy to propylene glycol and/or cyclosporine * Documented respiratory or anastomotic infections unless on appropriate antimicrobial therapy with evidence of clinical response * Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant * Women who are breastfeeding * Clinically significant bronchial stenosis unresponsive to dilation and/or stenting * Malignancies diagnosed within one year prior to screening (with the exception of non-melanomatous skin cancers)